| Autor: |
Alessandra D’Abramo, Serena Vita, Alessia Beccacece, Assunta Navarra, Raffaella Pisapia, Francesco Maria Fusco, Giulia Matusali, Enrico Girardi, Fabrizio Maggi, Delia Goletti, Emanuele Nicastri, ImmunoCOVID team, Tommaso Ascoli Bartoli, Nazario Bevilacqua, Angela Corpolongo, Patrizia De Marco, Maria Letizia Giancola, Gaetano Maffongelli, Andrea Mariano, Laura Scorzolini, Claudia Palazzolo, Silvia Rosati, Virginia Tomassi, Francesca Faraglia, Lavinia Fabeni, Martina Rueca, Silvia Meschi, Cesare Ernesto Maria Gruber |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Frontiers in Medicine, Vol 11 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2296-858X |
| DOI: |
10.3389/fmed.2024.1344267 |
| Popis: |
ObjectivesThe aim of the study was to describe a cohort of B-cell-depleted immunocompromised (IC) patients with prolonged or relapsing COVID-19 treated with monotherapy or combination therapy.MethodsThis is a multicenter observational retrospective study conducted on IC patients consecutively hospitalized with a prolonged or relapsing SARS-CoV-2 infection from November 2020 to January 2023. IC COVID-19 subjects were stratified according to the monotherapy or combination anti-SARS-CoV-2 therapy received.ResultsEighty-eight patients were enrolled, 19 under monotherapy and 69 under combination therapy. The study population had a history of immunosuppression (median of 2 B-cells/mm3, IQR 1–24 cells), and residual hypogammaglobulinemia was observed in 55 patients. A reduced length of hospitalization and time to negative SARS-CoV-2 molecular nasopharyngeal swab (NPS) in the combination versus monotherapy group was observed. In the univariable and multivariable analyses, the percentage change in the rate of days to NPS negativity showed a significant reduction in patients receiving combination therapy compared to those receiving monotherapy.ConclusionIn IC persistent COVID-19 patients, it is essential to explore new therapeutic strategies such as combination multi-target therapy (antiviral or double antiviral plus antibody-based therapies) to avoid persistent viral shedding and/or severe SARS-CoV-2 infection. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
